laagvlieger.x24hr.com,Radial,/Homorelaps512322.html,265/60R18,All,Falken,AT3W,$159,Wildpeak,Tire,114T,Terrain,-,Automotive , Tires Wheels , Tires $159 Falken Wildpeak AT3W All Terrain Radial Tire - 265/60R18 114T Automotive Tires Wheels Tires Falken Wildpeak AT3W All Terrain Arlington Mall Radial 114T 265 60R18 Tire - Falken Wildpeak AT3W All Terrain Arlington Mall Radial 114T 265 60R18 Tire - laagvlieger.x24hr.com,Radial,/Homorelaps512322.html,265/60R18,All,Falken,AT3W,$159,Wildpeak,Tire,114T,Terrain,-,Automotive , Tires Wheels , Tires $159 Falken Wildpeak AT3W All Terrain Radial Tire - 265/60R18 114T Automotive Tires Wheels Tires

Falken Wildpeak AT3W All Terrain Arlington Mall Radial 114T 265 Safety and trust 60R18 Tire -

Falken Wildpeak AT3W All Terrain Radial Tire - 265/60R18 114T

$159

Falken Wildpeak AT3W All Terrain Radial Tire - 265/60R18 114T

|||

Product description

The WILDPEAK A/T3W is engineered for adventure, any time and in any weather. The A/T3W combines aggressive off-road ability and rugged terrain driving without compromise on the pavement. An optimized tread design combined with a silica tread compound enable the A/T3W to excel in three areas: wear, winter, and wet performance. Designed for severe snow conditions, every A/T3W tire is qualified by the Rubber Manufacturers Association for the Three Peak Mountain Snow Flake (3PMSF) symbol. The A/T3W is packed with technology, from Falken’s patented 3D Canyon Sipes to an all-new proprietary lower sidewall. Full-depth sipes and grooves maintain consistent performance and appearance throughout the life of the tire.

Falken Wildpeak AT3W All Terrain Radial Tire - 265/60R18 114T

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA